Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Trastuzumab emtansine improves progression-free survival for HER2-positive breast cancer

Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA
Trastuzumab emtansine improves progression-free survival for HER2-positive breast cancer ( Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA )
3 Jun 2012

Recent developments in neoadjuvant therapy

Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany
Recent developments in neoadjuvant therapy ( Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany )
17 May 2012

Highlights and goals of IMPAKT 2012

Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium
Highlights and goals of IMPAKT 2012 ( Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium )
17 May 2012

PI3K and the heterogeneity of small tumour breast cancer

Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium
PI3K and the heterogeneity of small tumour breast cancer ( Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium )
17 May 2012

Molecularly characterising triple negative breast cancer

Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium
Molecularly characterising triple negative breast cancer ( Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium )
17 May 2012

Endocrine therapy and endocrine resistant breast cancer

Prof Mitch Dowsett – The Institute for Cancer Research, London, UK
Endocrine therapy and endocrine resistant breast cancer ( Prof Mitch Dowsett – The Institute for Cancer Research, London, UK )
17 May 2012

Neoadjuvant therapy and PCR through chemotherapy prior to surgery

Dr Michail Ignatiadis – Jules Bordet Institute, Brussels, Belgium
Neoadjuvant therapy and PCR through chemotherapy prior to surgery ( Dr Michail Ignatiadis – Jules Bordet Institute, Brussels, Belgium )
17 May 2012

Minimising recurrence by using most effective treatment

Prof Fabrice Andre – Institut Gustave Roussy, Paris, France
Minimising recurrence by using most effective treatment ( Prof Fabrice Andre – Institut Gustave Roussy, Paris, France )
17 May 2012

Overcoming drug resistance and targeting critical pathways

Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New York, USA
Overcoming drug resistance and targeting critical pathways ( Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New York, USA )
17 May 2012

Heterogeneity of tumours and the challenges of biomarker development

Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy
Heterogeneity of tumours and the challenges of biomarker development ( Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy )
17 May 2012

Targeting the PI3K/mTOR pathway

Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA
Targeting the PI3K/mTOR pathway ( Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA )
17 May 2012

Use of metformin against breast cancer

Prof Alastair Thompson – University of Dundee, UK
Use of metformin against breast cancer ( Prof Alastair Thompson – University of Dundee, UK )
17 May 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation